标准方案联合氯法齐明或莫西沙星治疗空洞性分枝杆菌肺病的临床结局。
Clinical Outcome with Standard Regimen plus Clofazimine or Moxifloxacin in Cavitary Mycobacterium avium Complex Pulmonary Disease.
机构信息
Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Asan Medical Centergrid.413967.e, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Department of Infectious Diseases, Asan Medical Centergrid.413967.e, University of Ulsan College of Medicine, Seoul, Republic of Korea.
出版信息
Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0052822. doi: 10.1128/aac.00528-22. Epub 2022 Nov 3.
Abstract
In this retrospective analysis including 173 patients in a tertiary referral center in South Korea, compared with the standard therapeutic regimen, clofazimine or moxifloxacin plus standard treatment regimen potentially did not induce a higher 1-year culture conversion rate in patients with Mycobacterium avium complex pulmonary disease who present with cavitary lesions (fibrocavitary or cavitary nodular bronchiectatic type).
摘要
在这项包括韩国一家三级转诊中心 173 名患者的回顾性分析中，与标准治疗方案相比，氯法齐明或莫西沙星联合标准治疗方案并未显著提高有空洞病变（纤维空洞型或空洞性结节性支气管扩张型）的鸟分枝杆菌复合群肺病患者的 1 年培养转阴率。
相似文献
1
Clinical Outcome with Standard Regimen plus Clofazimine or Moxifloxacin in Cavitary Mycobacterium avium Complex Pulmonary Disease.
Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0052822. doi: 10.1128/aac.00528-22. Epub 2022 Nov 3.
2
Treatment Outcomes of Cavitary Nodular Bronchiectatic-Type Mycobacterium avium Complex Pulmonary Disease.
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0226121. doi: 10.1128/aac.02261-21. Epub 2022 Aug 11.
3
Comparison of Treatment Outcomes of Cavitary Mycobacterium avium Complex Pulmonary Disease with Streptomycin or Amikacin Use.
Microbiol Spectr. 2023 Jun 15;11(3):e0474122. doi: 10.1128/spectrum.04741-22. Epub 2023 Apr 6.
4
Treatment outcomes of refractory MAC pulmonary disease treated with drugs with unclear efficacy.
J Infect Chemother. 2014 Oct;20(10):602-6. doi: 10.1016/j.jiac.2014.05.010. Epub 2014 Jun 26.
5
Efficacy of Fluoroquinolones as Substitutes for Ethambutol or Rifampin in the Treatment of Mycobacterium avium Complex Pulmonary Disease According to Radiologic Types.
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0152221. doi: 10.1128/AAC.01522-21. Epub 2021 Dec 20.
6
The Association Between Sputum Culture Conversion and Mortality in Cavitary Mycobacterium avium Complex Pulmonary Disease.
Chest. 2024 Sep;166(3):442-451. doi: 10.1016/j.chest.2024.03.027. Epub 2024 Mar 18.
7
Comparison of treatment outcomes between intermittent and daily regimens in non-cavitary nodular bronchiectatic-type complex pulmonary disease in relation to sputum smear results: a retrospective cohort study.
Antimicrob Agents Chemother. 2023 Nov 15;67(11):e0100323. doi: 10.1128/aac.01003-23. Epub 2023 Oct 16.
8
Efficacy of clofazimine-containing regimens for treatment of Mycobacterium avium complex-pulmonary disease in patients unsuitable for standard treatment regimen.
Int J Antimicrob Agents. 2024 Feb;63(2):107061. doi: 10.1016/j.ijantimicag.2023.107061. Epub 2023 Dec 14.
9
The natural history of non-cavitary nodular bronchiectatic Mycobacterium avium complex lung disease.
Respir Med. 2019 Apr;150:45-50. doi: 10.1016/j.rmed.2019.02.007. Epub 2019 Feb 12.
10
Neutrophil-Lymphocyte Ratio and Monocyte-Lymphocyte Ratio According to the Radiologic Severity of Complex Pulmonary Disease.
J Korean Med Sci. 2022 Oct 17;37(40):e292. doi: 10.3346/jkms.2022.37.e292.
引用本文的文献
1
Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine.
Infection. 2024 Jun;52(3):737-765. doi: 10.1007/s15010-024-02183-3. Epub 2024 Feb 8.
本文引用的文献
1
Efficacy of Fluoroquinolones as Substitutes for Ethambutol or Rifampin in the Treatment of Mycobacterium avium Complex Pulmonary Disease According to Radiologic Types.
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0152221. doi: 10.1128/AAC.01522-21. Epub 2021 Dec 20.
2
Treatment of severe complex pulmonary disease with adjunctive amikacin and clofazimine standard regimen alone: a retrospective study.
ERJ Open Res. 2021 Nov 22;7(4). doi: 10.1183/23120541.00466-2021. eCollection 2021 Oct.
3
Managing Mycobacterium avium Complex Lung Disease With a Little Help From My Friend.
Chest. 2021 Apr;159(4):1372-1381. doi: 10.1016/j.chest.2020.10.031. Epub 2020 Oct 17.
4
Minimal Inhibitory Concentration of Clofazimine Among Clinical Isolates of Nontuberculous Mycobacteria and Its Impact on Treatment Outcome.
Chest. 2021 Feb;159(2):517-523. doi: 10.1016/j.chest.2020.07.040. Epub 2020 Jul 24.
5
Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.
Eur Respir J. 2020 Jul 7;56(1). doi: 10.1183/13993003.00535-2020. Print 2020 Jul.
6
Sitafloxacin-Containing Regimen for the Treatment of Refractory Complex Lung Disease.
Open Forum Infect Dis. 2019 Mar 7;6(4):ofz108. doi: 10.1093/ofid/ofz108. eCollection 2019 Apr.
7
Drug-Penetration Gradients Associated with Acquired Drug Resistance in Patients with Tuberculosis.
Am J Respir Crit Care Med. 2018 Nov 1;198(9):1208-1219. doi: 10.1164/rccm.201711-2333OC.
8
British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD).
Thorax. 2017 Nov;72(Suppl 2):ii1-ii64. doi: 10.1136/thoraxjnl-2017-210927.
9
Outcomes of complex lung disease based on clinical phenotype.
Eur Respir J. 2017 Sep 27;50(3). doi: 10.1183/13993003.02503-2016. Print 2017 Sep.
10
Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection.
Chest. 2017 Oct;152(4):800-809. doi: 10.1016/j.chest.2017.04.175. Epub 2017 May 5.
Zotero 插件